Verisk Analytics CEO Lee Shavel Sells 2,500 Shares for $550,000

Verisk Analytics CEO Lee Shavel sold 2,500 shares on July 29, 2026 for ~$550k at a weighted-average $220.00 (post-trade 98,490 shares), executed under a non-discretionary Rule 10b5-1 plan from Dec 2025. The sale is small relative to his holdings and is not framed as a negative company signal. Still, the stock’s 1-year total return was -26.6% as of July 30, 2026, with TTM revenue of ~$3.1B and TTM net income of ~$885.5M, while analysts expect ~13% annualized earnings growth over the next two years.

Analysis

This filing is low-signal flow: a pre-planned 10b5-1 sale from a CEO with a still-meaningful residual stake tells us almost nothing about near-term fundamentals. The only market-relevant read-through is that management is not clearly using the current weakness to add, so sentiment can stay fragile while investors wait for proof that earnings can re-accelerate.

The real issue is not insider behavior but the gap between revenue growth and EPS conversion. That usually means either mix pressure, elevated reinvestment, or limited operating leverage — all of which matter more at a mid-20s earnings multiple than a simple software-like growth story. If VRSK cannot convert low-single-digit revenue growth into double-digit EPS growth, the stock can continue to de-rate even without any bad headline.

Second-order, this matters more for relative valuation than for outright fundamentals. If the market decides VRSK is a slower compounder, capital can rotate toward higher-quality data/analytics names with clearer capital return or growth optionality such as SPGI, MCO, or FICO. Contrarian view: the stock may already be pricing in too much skepticism after a weak year; if the next 1-2 quarters show margin stabilization and analyst EPS growth holds, this sale will prove irrelevant and the share price could mean-revert quickly.

Key Decisions for Investors

• No trade on the Form 4 alone; treat VRSK insider selling as non-actionable unless it becomes a pattern across multiple executives over the next 1-2 months.
• If long VRSK, hold into the next earnings print only if management can defend consensus EPS growth; otherwise reduce on any guide that implies sub-10% EPS growth and keep a hard stop on further multiple compression below ~20x forward earnings.
• Relative-value idea: long SPGI or MCO vs short VRSK for 1-3 months if you want exposure to the same analytics/data complex but with better capital-return optics and less execution risk; thesis breaks if VRSK re-accelerates margins or beats consensus materially.
• Watch item: if VRSK trades back above the recent high-200s/low-210s range without a corresponding upward EPS revision, consider a tactical put spread into earnings to express skepticism on valuation rather than on the business.